Additional doses of SARS-CoV-2 increase the antibody response in patients with IBD

Source / Publication

Source:

Quan J, et al. Poster 654. Presented at: Digestive Disease Week; 21-24 May 2022; San Diego (hybrid meeting).

Disclosure:
Quan has no relevant financial information.


We were unable to process your request. Please try again later. If this problem persists, contact [email protected]

SAN DIEGO – Seroconversion rates and antibody response increased significantly after the third dose of SARS-CoV-2 vaccine in patients with inflammatory bowel disease, according to the lecturer at Digestive Disease Week 2022.

“The responses to the third and fourth doses were significantly stronger than the two-dose regimen,” Joshua Quan, MSc, told participants a master’s degree at the University of Calgary Cumming School of Medicine. “Antibody responses also decreased over time from the second to the third dose, which really emphasizes the need for the third dose.”

Quan and colleagues conducted a multicenter prospective cohort study and identified 271 patients with IBD who received at least two doses of SARS-CoV-2 vaccine. Using the SARS-CoV-2 IgG II Quant Assay, patients analyzed the serological response 8 weeks after the second dose and then after the third dose. Seroconversion, defined as IgG levels of at least 50 AU / ml, served as the primary outcome. The investigators also evaluated the geometric mean titer (GMT) and categorized the results according to the previous history of COVID-19.

According to the results of the study, 100% of patients experienced seroconversion after the third dose (n = 96) versus 94.4% after the second dose (n = 175). GMT was also significantly higher in the cohort after the third dose compared to the cohort after the second dose (16,424 AU / ml vs. 3,261 AU / ml).

In 82 patients with serological data after the second and third doses, the seroconversion rate increased from 97.6% to 100% after the third dose. In addition, GMT increased after the third dose with an average difference of 11,384 AU / ml (P <0.0001) between the third and second dose, a significant difference between patients with a previous history of COVID-19 (11,682 AU / ml; 95% CI, 8,618-14,746; P <0.0001) and those without (8 194 AU / ml; 95% CI, 988-15 400).

According to Quan, preliminary data on the fourth dose showed similar reactions to the third dose.

“Another thing we really need is a correlation between antibody levels and real protection or reduced risk of infection,” Quan concluded. “This is especially true in the Omicron era, and this is a piece that our lab continues to work on.”

“In addition, we did not evaluate neutralizing antibodies or T cell immunity. … It would be important to understand them in relation to booster doses in relation to the new options. “

#Additional #doses #SARSCoV2 #increase #antibody #response #patients #IBD

Leave a Comment

Your email address will not be published. Required fields are marked *